16 assets in Myelodysplastic Syndrome With Excess Blasts-2

Therapeutic assets addressing Myelodysplastic Syndrome With Excess Blasts-2, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Gilteritinib Myelodysplastic Syndrome With Excess Blasts-2	Stichting Hemato-Oncologie voor Volwassenen Nederland	P3	BB (66)
Cytarabine Myelodysplastic Syndrome With Excess Blasts-2	Sumithira Vasu	P2	BB (64)
Azacitidine Myelodysplastic Syndrome With Excess Blasts-2	Aptose Biosciences Inc.	P2	B (62)
Midostaurin Myelodysplastic Syndrome With Excess Blasts-2	Stichting Hemato-Oncologie voor Volwassenen Nederland	P3	B (62)
Enasidenib Myelodysplastic Syndrome With Excess Blasts-2	Stichting Hemato-Oncologie voor Volwassenen Nederland	P3	B (60)
Ivosidenib Myelodysplastic Syndrome With Excess Blasts-2	Stichting Hemato-Oncologie voor Volwassenen Nederland	P3	B (60)
Venetoclax Myelodysplastic Syndrome With Excess Blasts-2	Aptose Biosciences Inc.	P2	B (60)
Cladribine Myelodysplastic Syndrome With Excess Blasts-2	M.D. Anderson Cancer Center	P2	B (57)
Cpx-351 Myelodysplastic Syndrome With Excess Blasts-2	Fred Hutchinson Cancer Center	P2	CCC (53)
Dexrazoxane Myelodysplastic Syndrome With Excess Blasts-2	M.D. Anderson Cancer Center	P2	CCC (53)
Gemtuzumab Ozogamicin Myelodysplastic Syndrome With Excess Blasts-2	M.D. Anderson Cancer Center	P2	CCC (53)
Idarubicin Myelodysplastic Syndrome With Excess Blasts-2	M.D. Anderson Cancer Center	P2	CCC (53)
Tuspetinib Myelodysplastic Syndrome With Excess Blasts-2	Aptose Biosciences Inc.	P1/2	CCC (48)
Anti-Pr1/Hla-A2 Monoclonal Antibody Hu8F4 Myelodysplastic Syndrome With Excess Blasts-2	M.D. Anderson Cancer Center	P1	CC (43)
Bxcl701 Myelodysplastic Syndrome With Excess Blasts-2	Eric Stephen Winer, MD	P1	CC (43)
lp-118 Myelodysplastic Syndrome With Excess Blasts-2	Newave Pharmaceutical Inc	P1	NR ()